9
Registered trials
2
Recruiting
7
Unique sponsors
4
Unique IMPs
8
Commercial trials
Drug classes (ATC)
—
ATC code not specified
8
A
Gastroenterology (ATC A)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
SGLT2 inhibitor
1 substance
Monoclonal antibody
1 substance
Phase III:
4
Phase II:
1
Other:
4
Phase III
4 trials-
RecruitingAstraZeneca AB CommercialBALCINRENONE, DAPAGLIFLOZIN; DAPAGLIFLOZIN
-
EndedNovo Nordisk A/S CommercialZILTIVEKIMAB
-
EndedNovo Nordisk A/S CommercialZILTIVEKIMAB
-
EndedAssistance Publique Hopitaux De Paris AcademicIMP not specified
Phase II
1 trial-
RecruitingPfizer Inc. CommercialPF-07328948
Other
4 trials-
EndedAdamed Pharma S.A. CommercialIMP not specified
-
EndedAdamed Pharma S.A. CommercialIMP not specified
-
EndedLaboratorios Cinfa S.A. CommercialIMP not specified
-
EndedTarchominskie Zaklady Farmaceutyczne Polfa S.A. CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Adamed Pharma S.A. | Commercial | 2 | Other | 0 |
| Novo Nordisk A/S | Commercial | 2 | Phase III | 0 |
| Laboratorios Cinfa S.A. | Commercial | 1 | Other | 0 |
| Tarchominskie Zaklady Farmaceutyczne Polfa S.A. | Commercial | 1 | Other | 0 |
| Pfizer Inc. | Commercial | 1 | Phase II | 1 |
| AstraZeneca AB | Commercial | 1 | Phase III | 1 |
| Assistance Publique Hopitaux De Paris | Academic | 1 | Phase III | 0 |
New trials by year
2023
1
2024
3
2025
4
2026
1